EMA recommends approval of VidPrevtyn Beta as a COVID 19 booster vaccine

EMA’s human medicines committee (CHMP) has recommended authorising the COVID-19 vaccine VidPrevtyn Beta as a booster in adults previously vaccinated with an mRNA or adenoviral vector COVID-19 vaccine.

VidPrevtyn Beta, developed by Sanofi Pasteur, contains a version of the spike protein found on the surface of the Beta variant of the SARS-CoV-2 virus. It also contains an ‘adjuvant’, a substance to help strengthen the immune responses to the vaccine.

EMA’s human medicines committee (CHMP) concluded that sufficiently robust data on the quality, safety and immunogenicity of the vaccine are now available to recommend its marketing authorisation in the EU.

The main studies conducted with VidPrevtyn Beta are two immunobridging trials, which compare the immune response induced by this new vaccine with that induced by an authorised comparator vaccine effective against the disease...